Skip to content

Internet-based writing therapy for the treatment of depressive symptoms in the Arabic-speaking world - A randomized controlled trial

Internet-based writing therapy for the treatment of depressive symptoms in the Arabic-speaking world - A randomized controlled trial - Ilajnafsy

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
DRKS
Registry ID
DRKS00016652
Enrollment
300
Registered
2019-02-04
Start date
2021-02-14
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32 F33 F34.1

Interventions

Group 1: Cognitive-behavioral therapy (CBT) The approximately five-week writing therapy developed on the basis of cognitive-behavioral therapeutic approaches. It consists of four modules (a total of

Sponsors

Zentrum Überleben gGmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Arabic-speaking Criteria for a current major depressive episode or for a persistent depressive disorder according to DSM-5 (American Psychiatric Association, 2013) are fulfilled Access to the Internet and a computer Private email address

Exclusion criteria

Exclusion criteria: Significant, current suicidal tendencies Severe depressive symptoms (BDI-II = 45) Symptoms too low (BDI-II 0-13) Criteria for post-traumatic stress disorder according to DSM-5 (American Psychiatric Association, 2013) are fulfilled Bipolar symptoms Psychotic symptoms Increased alcohol, drug or substance use within the last year Concurrent psychotherapeutic treatment Concurrent treatment with psychopharmaceuticals with unstable dose (changes in dose/type of medication in the last 4 weeks) Previous depression treatment by the "Ilajnafsy" programme

Design outcomes

Primary

MeasureTime frame
Changes in depressive symptoms: Patient Health Questionnaire (PHQ-9) Times of measurement: Baseline; 4 intermediate measurements during th intervention; post-treatment; follow-up (3- and 6-week follow-up) Changes in depressive symptoms: Beck Depression Inventory II (BDI-II) Times of measurement: Baseline; post-treatment; follow-up (3- and 6-week follow-up)

Secondary

MeasureTime frame
Secondary outcome measures: Somatic problems: Patient Health Questionnaire - somatization module (PHQ-15) Times of measurement: Baseline; post-treatment; follow-up (3- and 6-week follow-up) General anxiety: Generalized Anxiety Disorder Scale (GAD-7) Times of measurement: Baseline; post-treatment; follow-up (3- and 6-week follow-up) Life satisfaction: EUROHIS - Quality of Life Times of measurement: Baseline; post-treatment; follow-up (3- and 6-week follow-up) Social support: Multidimensional Scale of Perceived Social Support (MSPSS) Times of measurement: Baseline; post-treatment; follow-up (3- and 6-week follow-up) Traumatic experiences in the past: List of 25 potentially traumatic experiences and Life Events Checklist - 5 Extended Version (LEC-5) Times of measurement: Baseline (only if at least one trauma is specified in the trauma checklist:) Post-traumatic stress symptoms: PTSD checklist for DSM-5 (PCL-5) Post-traumatic cognitions and emotions: Posttraumatic Maladaptive Beliefs Scale (PMBS), Trauma Appraisal Questionnaire (TAQ), and Trauma-Related Guilt Inventory (TRGI) Posttraumatic Growth: Posttraumatic Growth Inventory (PTGI) Times of measurement: Baseline (only if a significant loss has been experienced:) Self-generated grief-specific questions Prolonged grief: Prolonged Grief Disorder-13 Questionnaire (PG-13) Times of measurement: Baseline; post-treatment; follow-up (3- and 6-week follow-up) Therapeutic relationship: Multiperspective Assessment of General Change Mechanisms in Psychotherapy (SACiP) Times of measurement: 3 Intermediate measurements during the intervention; post-treatment Therapy expectation: Patient Questionnaire on Therapy Expectation and Evaluation (PATHEV) Times of measurement: Baseline Evaluation questions: Satisfaction with the intervention is measured with three self-generated questions. Time of measurement: Post-treatment Side effects during the therapy: Inventory for the Assessment of Negati

Countries

Algeria, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco, Oman, Palestinian Territories, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, United Arab Emirates, Western Sahara, Yemen

Contacts

Public ContactSophie Clever

Zentrum Überleben gGmbH

s.clever@ueberleben.org+49 (0)30 – 303 906 71

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Sep 2, 2026